Search the GHTC website

Global health R&D delivers for Illinois

US government investment in global health R&D has delivered

$274.1 million
to Illinois research institutions
3,900+ new jobs
for Illinois
Illinois's top USG-funded global health R&D institutions

Illinois's top USG-funded global health R&D institutions

Northwestern University (including the Feinberg School of Medicine)
$108.6 million
University of Illinois at Chicago
$46.4 million
University of Chicago
$28.4 million
University of Illinois at Urbana-Champaign
$24.6 million
Minute Molecular Diagnostics
$23 million
Loyola University of Chicago
$14.3 million
Rush University Medical Center
$9.3 million
IIT Research Institute
$6.8 million
Chicago BioSolutions Inc.
$4.4 million
Rosalind Franklin University of Medicine and Science
$3.6 million
Lurie Children's Hospital of Chicago
$647 thousand
Illinois Institute of Technology
$554 thousand
Arete Biosciences
$535 thousand
Illinois State University
$530 thousand
DePaul University
$506 thousand
Tango Biosciences
$447 thousand
Integrated Protein Technologies
$360 thousand
Angiotensin Therapeutics
$300 thousand
$242 thousand
Southern Illinois University Carbondale
$215 thousand
American Health Sciences LLC
$122 thousand
$106 thousand

Illinois's top areas of global health R&D by USG funding

Other coronaviruses (including MERS, SARS)
Diarrheal diseases
Flioviral diseases (including Ebola, Marburg)
Neglected tropical diseases
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Reproductive health
Salmonella infections
Arenaviral hemorrhagic fevers (including Lassa fever)
Bacterial pneumonia & meningitis
Emergent non-polio enteroviruses (including EV71, D68)
Henipaviral diseases (including Nipah)
Hepatitis B
Hepatitis C
Multi-disease/health area R&D
Global health R&D at work in Illinois

During the COVID-19 pandemic, the Chicago-headquartered medical device company Abbott developed the widely used BinaxNOW line of rapid COVID-19 tests, which was first authorized for prescription use and then later for at-home self-testing. At the height of the pandemic, the company, which has several manufacturing facilities across the United States, provided more than 180 million tests for distribution by the US federal government to healthcare settings and homes and through the Access to COVID-19 Tools Accelerator global partnership, provided millions of its tests at low cost to low- and middle-income countries to expand diagnostic testing.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: The White House/Adam Schultz